2026-04-05T10:51:36Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1229052025-12-04T20:39:43Zcom_2072_1057col_2072_478800col_2072_478858col_2072_478917

NKX2-1 expression as a prognostic marker in early-stage non-small-cell lung cancer Moisés, Jorge Navarro Ponz, Alfons Santasusagna, Sandra Viñolas Segarra, Núria Molins López-Rodó, Laureano Ramirez, José Osorio, Jeisson Saco, Adela Castellano, Joan Josep Muñoz García, Carmen Morales, Sara Monzó Planella, Mariano Marrades Sicart, Ramon Ma. Càncer de pulmó Marcadors tumorals Lung cancer Tumor markers BACKGROUND: NKX2-1, a key molecule in lung development, is highly expressed in non-small cell lung cancer (NSCLC), particularly in lung adenocarcinoma (ADK), where it is a diagnostic marker. Studies of the prognostic role of NKX2-1 in NSCLC have reported contradictory findings. Two microRNAs (miRNAs) have been associated with NKX2-1: miR-365, which targets NKX2-1; and miR-33a, which is downstream of NKX2-1. We have examined the effect of NKX2-1, miR-365 and miR-33a on survival in a cohort of early-stage NSCLC patients and in sub-groups of patients classified according to the mutational status of TP53, KRAS, and EGFR. METHODS: mRNA and miRNA expression was determined using TaqMan assays in 110 early-stage NSCLC patients. TP53, KRAS, and EGFR mutations were assessed by Sanger sequencing. RESULTS: NKX2-1 expression was upregulated in never-smokers (P = 0.017), ADK (P < 0.0001) and patients with wild-type TP53 (P = 0.001). A negative correlation between NKX2-1 and miR-365 expression was found (ρ = -0.287; P = 0.003) but there was no correlation between NKX2-1 and miR-33a expression. Overall survival (OS) was longer in patients with high expression of NKX2-1 than in those with low expression (80.8 vs 61.2 months (P = 0.035), while a trend towards longer OS was observed in patients with low miR-365 levels (P = 0.07). The impact of NKX2-1 on OS and DFS was higher in patients with neither TP53 nor KRAS mutations. Higher expression of NKX2-1 was related to higher OS (77.6 vs 54 months; P = 0.017) and DFS (74.6 vs 57.7 months; P = 0.006) compared to low expression. The association between NKX2-1 and OS and DFS was strengthened when the analysis was limited to patients with stage I disease (P = 0.005 and P=0.003 respectively). CONCLUSIONS: NKX2-1 expression impacts prognosis in early-stage NSCLC patients, particularly in those with neither TP53 nor KRAS mutations. 2018-06-12T10:59:36Z 2018-06-12T10:59:36Z 2017-12-13 2018-06-12T10:59:36Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Reproducció del document publicat a: https://doi.org/10.1186/s12890-017-0542-z BMC Pulmonary Medicine, 2017, vol. 17, num. 197 https://doi.org/10.1186/s12890-017-0542-z cc-by (c) Moisés, Jorge et al., 2017 http://creativecommons.org/licenses/by/3.0/es info:eu-repo/semantics/openAccess BioMed Central Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)